Category «CORONAVIRUS»

Tixagevimab

(Heavy chain) QMQLVQSGPE VKKPGTSVKV SCKASGFTFM SSAVQWVRQA RGQRLEWIGW IVIGSGNTNY AQKFQERVTI TRDMSTSTAY MELSSLRSED TAVYYCAAPY CSSISCNDGF DIWGQGTMVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEF EGGPSVFLFP PKPKDTLYIT REPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPASIEK TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK (Light chain) EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY …

4-Hydroxy-TEMPO, TEMPOL, MBM-02, MTS 01

4-Hydroxy-TEMPO, TEMPOL, MBM-02, MTS 01 Molecular FormulaC9H18NO2 Average mass172.245 Da 2,2,6,6-Tetramethyl-4-hydroxypiperidinooxy 2,2,6,6-Tetramethyl-4-hydroxypiperidinooxy radical 2,2,6,6-Tetramethyl-4-piperidinol 1-oxyl CAS 2226-96-2 [RN] 4-hydroxy-1-oxyl-2,2,6,6-tetramethylpiperidine 4-Hydroxy-2,2,6,6-tetramethyl-1-piperidin-1-yloxy, free radical 4-Hydroxy-2,2,6,6-tetramethylpiperidine N-oxide 4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl TEMPOL CAS Registry Number: 2226-96-2 CAS Name: 4-Hydroxy-2,2,6,6-tetramethyl-1-piperidinyloxy Additional Names: 4-hydroxy-TEMPO; 4-hydroxy-2,2,6,6-tetramethyl piperidine N-oxide; 4-hydroxy-2,2,6,6-tetramethylpiperidinooxy Molecular Formula: C9H18NO2, Molecular Weight: 172.24 Percent Composition: C 62.76%, H 10.53%, N 8.13%, O 18.58% Literature References: Stable nitroxyl radical; water-soluble analogue of TEMPO, q.v. Functions as a …

Regdanvimab

(Heavy chain) QITLKESGPT LVKPTQTLTL TCSFSGFSLS TSGVGVGWIR QPPGKALEWL ALIDWDDNKY HTTSLKTRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI PGFLRYRNRY YYYGMDVWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK (Light chain) ELVLTQPPSV SAAPGQKVTI SCSGSSSNIG NNYVSWYQQL …

MVC COVID-19 vaccine, Taiwan’s covid vaccine

Medigen vaccine MVC COVID-19 vaccine MVC-COV1901 track it https://covid19.trackvaccines.org/vaccines/24/ MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. Medigen has combined forces with Dynavax, which offers an advanced adjuvant, CpG 1018 (also known as ISS-1018), for use with its vaccine. …

Soberana 02, FINLAY-FR-2

Soberana 02 FINLAY-FR-2 cas 2543416-58-4 A SARS-CoV-2 vaccine comprising a conjugate of the spike protein RBD domain with tetanus toxoid (Finlay Vaccine Institute of Cuba) Soberana 02, is a conjugate vaccine developed by Instituto Finlay de Vacunas.[517] Cuba[518] Iran[517] 517 Zimmer, Carl; Corum, Jonathan; Wee, Sui-Lee. “Coronavirus Vaccine Tracker”. The New York Times. Retrieved 30 June 2021. 518 Sesin, Carmen (14 …

CVnCoV, zorecimeran, CureVac COVID-19 vaccine

CVnCoV cas 2541470-90-8 An optimized, non-chemical modified mRNA encoding the prefusion-stabilized full-length spike protein of SARS-CoV-2 virus (Curevac) zorecimeran, CureVac COVID-19 vaccine CureVac/Bayer GSK NCT04674189 NCT04449276 NCT04515147 NCT04652102 EudraCT-2020-004066-19 mRNA-based vaccine PHASE 3 CVnCoV Humoral and cellular responses CD4+ T-cells, CD8+ T-cells N/A N/A Rhesus macaque [124] 124. Rauch S, Gooch K, Hall Y, Salguero FJ, …

COVAX-19

Vaxine Pty Ltd company logo Vaxine’s promising new COVID-19 vaccine candidate A new multivalent COVID-19 vaccine developed by Australian company Vaxine to tackle the new virus variants could be game-changer in the fight against COVID-19 The world desperately needs a vaccine that blocks virus transmission and protects against all the variants. Covax-19 vaccine may soon …

ARCT-021 (LUNAR-COV19)

ARCT-021 (LUNAR-COV19) cas 2541451-24-3 A lipid-enabled and UnlockedNucleomonomer Agent modified RNA (LUNAR) of self-replicating RNA for vaccination against spike protein of SARS-CoV-2 (Arcturus) Self-replicating RNA vaccine Arcturus Therapeutics and Duke-NUS Medical School, Singapore OriginatorArcturus Therapeutics ClassCOVID-19 vaccines; RNA vaccines; Viral vaccines Mechanism of ActionImmunostimulants Orphan Drug StatusNo New Molecular EntityNo Available For LicensingYes – COVID 2019 …

IIBR-100

IIBR-100 Brilife Recombinant vesicular stomatitis virus (rVSV) vaccine Israel Institute for Biological Research Hadassah Medical Center; Sheba Medical Center Hospital The SARS-CoV-2 virus is responsible for the COVID-19 pandemic. The pandemic emerged from Wuhan Province in China in December 2019 and was declared by the WHO Director-General a Public Health Emergency of International Concern on …

ABDALA, CIGB-66

ABDALA CIGB-66, is a COVID-19 vaccine Cuba says Abdala vaccine 92.28% effective against coronavirus The announcement came just days after the government said another homegrown vaccine, Soberana 2, has proved to be 62% effective with just two of its three doses. https://health.economictimes.indiatimes.com/news/industry/cuba-says-abdala-vaccine-92-28-effective-against-coronavirus/83735386 June 22, 2021, 10:03 IST Havana: Cuba said on Monday that its three-shot Abdala vaccine against the coronavirus has …